Owens & Minor (NYSE:OMI) Releases Q4 2024 Earnings Guidance

Owens & Minor (NYSE:OMI) issued an update on its fourth quarter 2024 earnings guidance on Monday morning. The company provided earnings per share guidance of 0.520-0.550 for the period, compared to the consensus earnings per share estimate of 0.530. The company issued revenue guidance of $2.7 billion-$2.7 billion, compared to the consensus revenue estimate of $2.7 billion. Owens & Minor also updated its FY 2024 guidance to 1.500-1.530 EPS.

Owens & Minor Stock Down 1.6 %

Shares of Owens & Minor stock traded down $0.15 on Wednesday, hitting $8.99. The company had a trading volume of 643,193 shares, compared to its average volume of 871,121. The company has a debt-to-equity ratio of 2.11, a quick ratio of 0.45 and a current ratio of 1.09. The stock has a 50 day moving average of $13.69 and a 200-day moving average of $14.24. Owens & Minor has a 1 year low of $8.75 and a 1 year high of $28.35. The stock has a market capitalization of $693.30 million, a price-to-earnings ratio of -13.83, a P/E/G ratio of 0.40 and a beta of 0.48.

Owens & Minor (NYSE:OMI) last released its earnings results on Monday, November 4th. The company reported $0.42 EPS for the quarter, topping the consensus estimate of $0.41 by $0.01. The business had revenue of $2.72 billion for the quarter, compared to the consensus estimate of $2.68 billion. Owens & Minor had a positive return on equity of 14.60% and a negative net margin of 0.46%. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.44 earnings per share. As a group, sell-side analysts forecast that Owens & Minor will post 1.49 earnings per share for the current year.

Wall Street Analyst Weigh In

OMI has been the topic of several research reports. Citigroup reduced their price objective on Owens & Minor from $21.00 to $18.50 and set a “buy” rating on the stock in a report on Tuesday, November 5th. Barclays decreased their price target on Owens & Minor from $18.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 5th. UBS Group dropped their price objective on shares of Owens & Minor from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, November 5th. Finally, Robert W. Baird decreased their price objective on shares of Owens & Minor from $15.00 to $14.00 and set a “neutral” rating for the company in a research note on Tuesday. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Owens & Minor currently has an average rating of “Hold” and an average price target of $18.50.

Insider Activity at Owens & Minor

In related news, CFO Jonathan A. Leon sold 5,282 shares of the business’s stock in a transaction that occurred on Thursday, November 21st. The stock was sold at an average price of $11.82, for a total value of $62,433.24. Following the transaction, the chief financial officer now directly owns 130,822 shares of the company’s stock, valued at approximately $1,546,316.04. The trade was a 3.88 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 2.62% of the stock is owned by corporate insiders.

Owens & Minor Company Profile

Owens & Minor, Inc, together with its subsidiaries, operates as a healthcare solutions company worldwide. It operates through Products & Healthcare Services and Patient Direct segments. The Products & Healthcare Services segment offers a portfolio of products and services to healthcare providers and manufacturers.